AstraZeneca moves US listings to NYSE in 2026

AstraZeneca PLC is reorganising its US market presence by completing a direct listing of its ordinary shares and US debt securities on the New York Stock Exchange.

Rhea-AI Filing Summary

AstraZeneca PLC is reorganising its US market presence by completing a direct listing of its ordinary shares and US debt securities on the New York Stock Exchange. The move is part of a shareholder approved plan to create a harmonised listing structure that supports a single global listing framework for investors.

The company has given notice that its American Depositary Shares, which represent ordinary shares on a two-for-one basis, and certain debt securities currently listed on Nasdaq are expected to cease trading there on 30 January 2026. AstraZeneca’s ordinary shares and these debt securities are expected to begin trading on the NYSE on 2 February 2026 under the ticker symbol AZN. After these changes, investors will be able to trade ordinary share interests across the London Stock Exchange, Nasdaq Stockholm and the NYSE.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What listing change did AstraZeneca (AZN) announce for its shares and debt?

AstraZeneca announced it will complete a direct listing of its ordinary shares and certain US debt securities on the New York Stock Exchange as part of a harmonised global listing structure.

What happens to AstraZeneca (AZN) American Depositary Shares on Nasdaq?

AstraZeneca has provided notice of voluntary withdrawal of its American Depositary Shares from Nasdaq. The listing of these ADSs on Nasdaq is expected to cease on 30 January 2026.

When will AstraZeneca ordinary shares start trading on the NYSE?

The direct listing on the NYSE is expected to be effective after market close on 30 January 2026, with AstraZeneca’s ordinary shares expected to commence trading on the NYSE on 2 February 2026.

Will AstraZeneca’s ticker symbol change with the NYSE listing?

No. AstraZeneca states that the ticker symbol for its ordinary shares on the New York Stock Exchange will remain "AZN".

On which exchanges will AstraZeneca ordinary shares be tradable after the changes?

Following implementation of the harmonised listing structure, shareholders will be able to trade interests in AstraZeneca’s ordinary shares on the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange.

What did AstraZeneca say about its debt securities in this listing update?

The company plans to list its relevant debt securities on the NYSE and withdraw their listing from Nasdaq. It refers investors to its website for details on outstanding US dollar-denominated and US-listed debt securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 07:18 AM EST Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of January 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

AstraZeneca to complete direct listing on NYSE

20 January 2026

AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange

Ticker symbol for ordinary shares will remain AZN

AstraZeneca PLC ("AstraZeneca") today provided notice of the voluntary withdrawal from listing on The Nasdaq Stock Market LLC ("Nasdaq") of (i) its American Depositary Shares (the "ADSs"), representing AstraZeneca's ordinary shares of $0.25 each (the "Ordinary Shares") on a two-for-one basis and (ii) debt securities issued by AstraZeneca or its wholly-owned subsidiary AstraZeneca Finance LLC and guaranteed by AstraZeneca (the "Debt Securities"). As previously announced on 29 September 2025, AstraZeneca plans to complete a direct listing of its Ordinary Shares and the Debt Securities on the New York Stock Exchange (the "NYSE"), which will be effective after market close on 30 January 2026. The direct listing is a part of AstraZeneca's shareholder approved plan to harmonise its share listing structure to deliver a global listing for global investors in a global company. Following implementation of the Harmonised Listing Structure, shareholders will be able to trade their interests in the Ordinary Shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE.

The listing of the ADSs and the Debt Securities on Nasdaq is expected to cease on 30 January 2026 and the Ordinary Shares and Debt Securities are expected to commence trading on the NYSE from Monday, 2 February 2026. The Ordinary Shares will continue to be listed under the ticker symbol "AZN".

Debt securities

For details on the Debt Securities, including outstanding US dollar-denominated and US-listed debt securities please visit https://www.astrazeneca.com/investor-relations/debt-investors.html.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. The contents of AstraZeneca's website do not form part of this document and no one should rely on such websites or the contents thereof in reading this document.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 20 January 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary